Seeking Alpha

Three members of an independent FDA advisory panel say they received advanced information ahead...

Three members of an independent FDA advisory panel say they received advanced information ahead of U.S. regulators in May 2010 regarding the rejection of a drug from InterMune (ITMN -2.5%), which is now at the heart of a trading investigation of SAC Capital. ITMN’s shares fell 5.4% the day before the company announced the rejection. However, others at the FDA were also aware of the rejection too, and there’s no evidence the 11 panelists did anything wrong.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)